MedTrace Logo

Allopurinol and Pathogenesis of Cirrhosis

NCT07033533 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-24

No results posted yet for this study

Summary

Hepatic decompensation is a common healthcare issue

. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Conditions

  • Cirrhoses, Liver

Interventions

DRUG

Allopurinol Tablet

allopurinol 300

DRUG

Placebo

placebo tablet

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-03-01
Completion
2024-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07033533 on ClinicalTrials.gov